A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

In the face of growing global healthcare challenges, breast cancer remains a key area of ​​concern due to its increasing prevalence worldwide. The Global Breast Cancer Therape ...

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative breast ...

Mesothelioma is an aggressive cancer that forms in the lining of the lungs or abdomen and is linked to breathing in or ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies ...